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Utilization of the clinical laboratory for the
implementation of concussion biomarkers
in collegiate football and the necessity of
personalized and predictive athlete specific
reference intervals
Stefanie Schulte1,2, Natalie N. Rasmussen3,6, Joseph W. McBeth4, Patrick Q. Richards4, Eric Yochem4,
David J. Petron5 and Frederick G. Strathmann3,6*

Abstract
Background: A continued interest in concussion biomarkers makes the eventual implementation of identified
biomarkers into routine concussion assessment an eventual reality. We sought to develop and test an interdisciplinary
approach that could be used to integrate blood-based biomarkers into the established concussion management
program for a collegiate football team.
Methods: We used a CLIA-certified laboratory for all testing and chose biomarkers where clinically validated testing
was available as would be required for results used in clinical decision making. We summarized the existing methods
and results for concussion assessment across an entire season to identify and demonstrate the challenges with the
eventual integration of a parallel process using blood-based tests for concussion management. We analyzed the results
of the biomarkers chosen for trends consistent with the outcome assessments provided from the current concussion
management protocols.
Results: Baseline samples were collected with three additional post-concussion samples collected at three separate
time points from players with a diagnosed concussion (n = 12). A summary of results from currently used concussion
assessment tools were compared to the representative biomarkers S100B and NSE results. Nine sport-related
concussions occurred during practice and three during play. For S100B, 50 % had follow-up testing results lower than
the post-injury result. In contrast, 92 % of NSE follow-up results were lower than post-injury. One hundred percent of
the results for S100B and NSE were within the athlete-derived reference intervals upon return-to-play and season end.
Conclusions: The reported workflow provides a framework for the eventual implementation of biomarkers for
concussion assessment into existing assessment protocols and strengthens the need for reliance on clinical
laboratory testing. Athlete-specific reference intervals will be required to adequately interpret results.
Keywords: Sports-related concussion, Biomarker panel, Predictive diagnostics, Blood test, Collegiate athletes,
Football, Traumatic brain injury, S100B, NSE
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Background
Sport-related concussion (SRC) continues to receive tremendous global attention. It has been estimated that up to
3.8 million SRCs occur in the USA each year [1]. Approximately 5.8 % of all collegiate athletic injuries are SRCs with
higher rates in contact sports such as football [2]. Recent
findings suggest that collegiate football players who sustained one SRC in a season are more likely to sustain a second concussion in the same season compared to uninjured
players. Additionally, collegiate football players are more
likely to return-to play (RTP) early following concussion
than athletes in other sports [3]. Accordingly, collegiate
football players represent an important at risk population
regarding concussion assessment and treatment.
Given the amount of SRC in collegiate football and the
potential risk for long-term consequences associated with
RTP, greater focus on the management and monitoring of
SRC from multiple aspects is required and ongoing. Since
various concussion laws endeavor to increase athletes’ protection from the potential consequences of SRC, the Sports
Concussion Management Policy of Utah High School
Activities Association (UHSAA) serves as a standard for
Utah’s concussion management in high schools though
collegiate athletics are arguably held to higher standards
[4]. This policy recommends computerized neuropsychological assessment (CNA) which includes a pre‐season
baseline to allow comparison of concussed athletes’
performance to their baseline values. Accordingly, the
Concussion Program of the University of Utah, Department
of Athletics implemented CNA as part of a comprehensive
physical and neurocognitive assessment for Utah’s collegiate
football players [5]. Furthermore, the neurophysiological
test Balance Error Scoring System (BESS) and the Sport
Concussion Assessment Tool 2 ((SCAT2) at the time of
manuscript preparation; currently superseded by SCAT3)
are standardized sideline tools and follow-up evaluations
for concussed football players. Additionally, a concussion
symptom chart/checklist based on the University of Utah
Sports Medicine Concussion Management Plan is used
to monitor athletes’ medical outcome. Even though these
neurophysiological tests are relatively well-established testing methods in concussion management, recent studies
have expressed concerns about the reliability and validity
of neuropsychological tests for SRC assessment [6, 7]. Controversies regarding appropriate concussion diagnosis and
management could potentially lead to premature RTP
decisions [8]. Determining the RTP accurately can be challenging due the variability in presentation of concussion
symptoms, and a lack of objective data indicating when full
recovery has occurred [9, 10]. Accordingly, the accurate
diagnosis of SRC and determination of RTP criteria are
crucial for a collegiate football player to recover from SRC.
The need for accurate diagnosis and management of
SRC in an unbiased manner has resulted in efforts to
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identify blood-based biomarkers which are capable of
documenting quantifiable biological changes directly related to physiological trauma [11, 12]. The clinical use of
blood-based biomarkers in addition to existing SRC
assessment presents multiple advantages. Firstly, bloodbased biomarker measurement is minimally invasive and
causes less cost for processing and analysis. Secondly, an
accurate determination or exclusion of SRC would assist
in the decision of whether further brain imaging or
following-up testing is necessary. Thirdly, if appropriate
biomarker concentrations could be correlated with the
extent of SRC and progression of the injury, results could
be used to objectively assess recovery time and RTP [13].
The majority of proposed biomarkers for concussion assessment have been identified and tested in the research
setting. However, two extensively studied protein biomarkers for brain injury, S100B and neuron-specific enolase
(NSE) [14], are available clinically. S100B concentrations of
less than 0.1–0.12 μg/l have been shown to be a reliable
tool to predict a normal CT scan and to support the
clinician’s decision not to perform CT imaging [15, 16].
Furthermore, serum S100B concentrations greater than
0.027 ng/mL were found to significantly correlate with
more than 90% of abnormal cerebrospinal-fluid albumin
quotient results, the current gold standard for determining blood-brain barrier dysfunction (BBBD) [17]. Thus,
the measurement of S100B is used in emergency room
settings to rule out concussions [15, 18]. Serum NSE levels
of more than 16.32 μg/L are considered to be pathological
[19]. NSE is a marker which directly reflects traumatic
damage of the neurons [20]. Also, NSE has been shown to
be 87 % sensitive and 82.1 % specific in predicting poor
neurologic outcome in concussed patients [21]. In terms
of predicting intracranial pathology and long lasting neurocognitive disability, early concentration peaks of both
S100B and NSE have been shown to be sensitive indicators following concussion and BBBD [14, 22]. Thus, the
markers S100B and NSE have demonstrated reasonable
prognostic value for concussion management despite
the existence of conflicting data [22, 23].
Given the potential value and promise of biomarker
integration into athletic concussion assessment, the development of a successful workflow for their inevitable
integration is crucial. The use of blood-based biomarkers
in SRC management also implies the practicality of
venipuncture and blood processing in situations and
under circumstances that are not in line with the WHO
guidelines [24]. Errors and delays in the blood collection
and processing system can affect the diagnostic process
[25]. In the present study, we sought to develop and test
an interdisciplinary approach for the integration of
blood-based biomarkers into the established concussion
management program for the collegiate football team at
the University of Utah using S100B and NSE as example
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biomarkers. The selection of S100B and NSE was based
largely on their availability as clinically validated tests
that could be conducted in a CLIA-certified central laboratory facility in contrast to a research setting. Herein,
we present an established and successful interdisciplinary work flow for blood collection, on-site sample processing, and central laboratory testing for the duration
of an entire collegiate football season. The included data
provide a summary of the concussion assessment tools
available at the time the study was conducted and
demonstrate the successful integration of biomarker
monitoring into collegiate athletics.

Methods
This project and its protocols were approved by the
University of Utah Institutional Review Board (IRB
#00061977). The demographic summary for the included
athletes (all male) was as follows: age range, 18 to 26 years;
mean age, 21 years. For the baseline venipuncture, athletes
were separated into two groups of approximately 60 athletes with the baseline collection occurring within 2 h
post-physical activity that did not include full contact play.
Five certified phlebotomists were present for the baseline
venipuncture with each group of athletes taking approximately 1 h to complete. Individual venipuncture kits were
organized to include all necessary materials for the
venipuncture, and similar draw kits were used for the
remaining venipunctures throughout the season (Additional file 1: Table S1). For post-injury venipunctures, two
assistant athletic trainers with access to the athletes conducted phlebotomy training and met the required minimum for the observed venipunctures with certified
phlebotomists prior to the start of the season. A
Champion E-33 Series centrifuge (Ample Scientific LLC,
Norcross, GA) was purchased for sample processing. Sample collection procedures were in line with those established for clinical testing including separation of the
serum from the cells within 2 h and stored refrigerated
until next day pick-up for transfer to the laboratory.
Samples were collected in red-top tubes, allowed to
clot, and were separated from the cells within 2 h of
being drawn. Aliquots were stored at −70 °C until testing.
CanAg® NSE and S100B enzyme-linked immunosorbent
assay kits (Fujirebio Diagnostics, Inc.,Göteborg, Sweden)
were used following manufacturer directions provided in
the package inserts, and testing was conducted in a CLIAcertified laboratory environment consistent with established laboratory Standard Operating Procedure. For the
NSE test, 96-well plates were washed with a buffered wash
solution, then 25 μL of calibrators, QC material, and subject samples were added to each well in duplicate as per
manufacturer recommendation. A 100 μL of antibody solution was added to the wells and the plate was incubated,
shaking for 1 h at room temperature. Following
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incubation, wells were rinsed with the buffered wash solution and 100 μL of substrate was added. After 30 min of
incubation at room temperature, 100 μL of stop solution
was added to each well. The plates were read at 405 nm
using a Spectramax® Plus384 spectrophotometer (Molecular Devices Corp., Sunnyvale, CA). A calibration
curve of absorbance (OD) versus concentration (μg/L)
using a quadratic fit was generated by the plate reader
software. Concentrations of QC and subject samples were
automatically determined from the curve by the software.
For the S100B test, 96-well plates were rinsed with a buffered wash solution. Fifty microliter of calibrators, QC material, and subject samples were added to each well in
duplicate, followed by 100 μL of biotin anti-S100. The
plate was shaken at room temperature for 2 h, and then
rinsed with the wash buffer solution. A 100 μL of tracer
working solution was added to each well and the plate
was incubated for 1 h, shaking at room temperature. After
incubating, wells were rinsed with buffered wash solution
and 100 μL of substrate was added. After 30 min, 100 μL
of stop solution was added and plates were read at
405 nm using the same spectrophotometer listed above. A
calibration curve of absorbance (OD) versus concentration
(μg/L) using a quadratic fit was generated by the plate
reader software. Concentrations of QC and subject
samples were automatically determined from the
curve by the software. Analytical limits of quantification are 1–150 μg/L for NSE and 12–3500 ng/L for
S100B.
Duplicate sample results all had CVs <15 %; no repeats
were necessary. Two levels of NSE QC material were
pooled in house using de-identified patient samples previously tested for NSE. CanChek Tumor Marker Control
Sera Levels 1 and 2 (IBL America, Inc.) were used as
QC material for S100B. QC quantitated within two SDs
of the mean established by the clinical laboratory for
the current lots of material.
Concussion assessment tools

RTP decision management focuses mostly on signs and
symptoms of neuropsychological test batteries [26, 27].
In accordance with Shane et al. [28], we chose to use the
symptoms sections of the neuropsychological assessment
tools. The symptom charts of SCAT2, CNA, and the
University of Utah Sports Medicine Concussion Symptom
Checklist compromise 22 similar symptoms with a
symptom scoring from 0 (none) to 6 (severe).
SCAT2

The Sport Concussion Assessment Tool 2 (SCAT2) was
developed to replace the original SCAT during the “3rd
International Conference on Concussion in Sport” in
2008 and was in place at the time of manuscript preparation [29]. The SCAT2 was widely established as the
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standardized technique to evaluate, assess, and manage
SRC for individuals older than 10 years with the end
goal of safely returning the athlete to play [30]. SCAT2
enabled medical and health professionals to assess
concussion in a standardized way by evaluating seven
areas including symptoms, physical signs, Glasgow Coma
Scale, sideline assessment using Maddocks score, cognitive assessment, balance, and coordination. The symptom
chart of SCAT2 required the participant to score
him/herself on 22 symptoms on a scale from 0 (none)
to 6 (severe) based on how he or she is feeling. A
total number of symptoms (max. 22) and a symptom
severity score (max. 22 * 6 = 132) is calculated. Furthermore,
the participant was asked if physical or mental activity
worsens the symptoms. In the event that the tester knows
the participant well prior to the injury, he or she was asked
how different the participant is acting compared to his or
her usual self. The score of the symptom chart influences
the total score of SCAT2. The SCAT3 is currently in
use, and key differences are described elsewhere [30].
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BESS

The Balance Error Scoring System (BESS) is a balance
test developed to provide clinicians with an inexpensive
and practical tool for the assessment of postural stability
[33]. The BESS is frequently used for the assessment of
postural stability in concussed athletes [34]. The test is
comprised of three parts: double-leg stance (hands on
the hips and feet together), single-leg stance (standing
on the non-dominant leg with hands on hips), and a tandem stance (non-dominant foot behind the dominant
foot) in a heel-to-toe fashion. Each of the three parts is
executed on a firm and on a foam surface (eyes closed,
20 s each). The errors are counted during each trial, defined as (i) lifting hands off iliac crest, (ii) opening eyes,
(iii) stepping, stumbling or falling, (iv) remaining out of
Table 1 Comparison of Symptom Charts used for concussion
assessments
General/cerebral

Symptoms

SCAT2

CNA

CSC

Nausea or vomiting

*

*

*

Dizziness

*

*

*

Computerized neuropsychological assessment (CNA)

Sensitivity to light

*

*

*

Immediate Post-Concussion Assessment and Cognitive
Testing (ImPACT) is the most widely used computerized
neuropsychological test in the USA [31]. The ImPACT
test compromises four sections including a demographic
profile and health history questionnaire, current concussion symptoms and conditions, baseline and post-injury
neurocognitive tests, and a graphic display of ImPACT
test scores [32]. As in SCAT2, the symptom chart of ImPACT covers 22 symptoms with most of the symptoms
being congruent and ranks the symptoms on a scale
from 0 being “symptom free” to 6 being “severe”.

Sensitivity to noise

*

*

*

Feeling slowed down

*

*

*

Feeling like “in a fog”

*

*

*

“Don’t feel right”

*

Fatigue or low energy

*

*

*

Confusion

*

Drowsiness

*

*

*

Headache

*

*

*

“Pressure in head”

*

Neck Pain

*
*

*

*

*

University of Utah Sports Medicine Concussion Symptom
Checklist (CSC)

In agreement with the SCAT2 and the CNA chart, the
University of Utah Sports Medicine Concussion Symptom
Checklist covers 22 symptoms. The symptoms and the
scoring are identical with the CNA symptom chart. Each
concussed student athlete completed the checklist
with a certified athletic trainer daily. The total symptom score was used in assessing the athlete’s progress
and progression through the return-to-play protocol
as defined in the University of Utah Sports Medicine
Concussion Management Plan. When the symptom
score was equal to zero, the player was no longer required
to complete the symptom checklist. It was adopted
from the CNA tool in an attempt to maintain continuity when comparing the symptom scores between
the three different evaluation tools. This list and the CNA
test could be completed over several different days,
while the SCAT2 test was only administered at the
time of a suspected SRC.

Pain/missensation

Numbness or tingling
Impaired function

Emotions

Other

Vision

*

Balance

*

*

*

Concentration

*

*

*

Memory

*

*

*

Sleep

*a

*a,b

*a,b

More emotional

*

*

*

Irritability

*

*

*

Sadness

*

*

*

Nervous or anxious

*

*

*

c,d

*

*c

The presented data compare the symptom charts of the Sport Concussion
Assessment Tool 2 (SCAT2), the Computerized Neuropsychological Assessment
(CNA), and the CSC (a symptom scale based on the University’s Concussion
Program). All symptom charts rank and score the symptoms on a scale from 0
(none) to 6 (severe)
a
Trouble falling asleep
b
Sleeping more/less than usual
c
Symptoms get worse with physical/mental activity? (Y/N)
d
Is athlete acting different compared to the usual self? (no
different/very different/unsure)

Schulte et al. The EPMA Journal (2016) 7:1
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Table 2 Time difference between the date of injury and post-injury assessments
Δ DOI–DOA post

Mean ± STDEV

Median

BESS

0–7 d

1.8 ± 2.2 d

1.0 d

CNA

1–7 d

1.9 ± 1.8 d

1.0 d

SCAT2

15 min–158 hrs

28:26 ± 48:48 hrs

5:07 hrs

CSC

1–19 d

4 ± 5.5 d

2.0 d

Biomarker (S100B and NSE)

15 min–17:28 hrs

5 ± 7:08 hrs

2:00 hrs

This table displays the time difference (Δ) between the date of injury (DOI) and the date of the first concussion assessment following the injury (DOA post) using
the most suitable unit of time in days (d), hours (hrs), and minutes (min). Mean and standard deviation are expressed in Mean ± STDV. The assessment includes
the Balance Error Scoring System (BESS), Computerized Neuropsychological Assessment (CNA), the Sport Concussion Assessment Tool 2 (SCAT2), the CSC (a symptom
scale based on the University’s Concussion Program) and the blood-based biomarkers S100 Beta (S100B) and neuron-specific enolase (NSE)

test position for more than 5 s, (v) moving the hip into
more than 30° flexion or abduction, and (vi) lifting
forefoot or heel [33].

for biomarker significance determination followed by a
Tukey HSD post hoc analysis. Statistical analysis and
figure generation were accomplished using R [35] with the
ggplot2 graphics package [36], respectively.

Statistics

Given the nature of this study and the small sample size,
the authors chose to analyze the data in a largely descriptive manner to avoid a misrepresentation and misinterpretation of the results [4]. ANOVA was performed

Ethical considerations

This project and its protocols were approved by the
University of Utah Institutional Review Board (protocol #00061977) and required informed consent for

Fig. 1 NSE and S100B results from the baseline, post-injury (post), return-to-play (RTP) and end-of-play (EOP) venipunctures. Upper and lower
hinges correspond to the 25th and 75th percentiles, respectively. The upper whisker extends from the 75th percentile to the highest value within
1.5 times the interquartile range (IQR). The lower whisker extends from the 25th percentile to the lowest value within 1.5 times the IQR. Data
beyond the whiskers are outliers and plotted as open circles. Individual data points (solid black) are overlaid. The horizontal lower dashed line, solid
black line, and upper dashed line represent the 2.5, 50, and 97.5 non-parametric percentiles, respectively, of the baseline results. The established
reference interval that includes the middle 95 % of the baseline data was determined to be 6.7 to 23.9 μg/L for NSE and 32 to 250 ng/L for
S100B. A statistically significant difference was observed between the post and EOP venipunctures for NSE
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participation. All included athletes were consented at
the time of the baseline sample blood draw event
consistent with IRB requirements.

Results
A comparison of the Symptom Charts currently used is
provided in Table 1. In total, 12 SRCs in 11 athletes
(20.6 ± 2.2 years) were reported during the football season between August and November in 2013. Nine SRCs
were reported occurring during a practice session and
three during a play. Seven SRCs were caused by a direct
hit to the athlete’s head by another athlete’s helmet (six)
or a head collision with an object (one). Two SCRs were
reported after a hard hit to the body, and three SRC reports were made after an unknown course of events
(two) and after an unrelated injury (one). Less than half
of the SRCs were self-reported (five). The majority was
discovered by either an athletic trainer (five) or by the
position coach (two). On average, concussed athletes began
the return-to-play protocol after 2 days (1.9 ± 2.3 days) with
a range of 3–48 days. For reasons of safety, two athletes
were medically disqualified to return to play. RTP decisions
were made based on a previously reported strategy consistent with current recommendations and guidelines [12].
As of the current state evaluation and a critical aspect
to understanding how best to implement biomarkers
into the workflow, we evaluated the time difference between the date of injury and the post-injury assessment
for the concussion assessment tools in use. Summary
data for the time differences for each Symptom Chart
are provided in Table 2. In addition, a summary of the
time difference between injury and the initial venipuncture
are included. The time deference data for injury assessments and venipuncture indicate a wide distribution
range that is consistent with the variability in symptom
presentation and time to reporting of a sustained injury.
The mean and median time differences for the post-injury
venipuncture indicate adequate compliance with expectations of a venipuncture occurring within 2 h of the reported
injury; however, the wide range further highlights the
difficulty with reliance on self-reporting.
One of the challenges in applying clinical testing to a
unique population such as collegiate athletes is the lack
of suitable reference intervals for categorizing patient
results in an appropriate context. Further, previously
established “cutoffs” used in determining clinical sensitivity and specificity are expected to vary widely among
differing populations and clinical circumstances. Figure 1
provides a summary of the NSE and S100B results for
the baseline, post-injury, return-to-play and end-of-play
venipunctures. In order to provide a population appropriate reference interval, baseline values (n = 127) were
used to establish a non-parametric reference interval
using the 2.5and 97.5 % of the data for NSE and S100B.
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The established reference intervals were 6.7 to 23.9 μg/L
for NSE and 32 to 250 ng/L for S100B. In comparison,
reference intervals based upon healthy, non-athletes
commonly used in clinical interpretations are 3.7 to
8.9 μg/L for NSE and 0 to 96 ng/L for S100B. A statistically significant difference was observed between the
post-injury and end-of-play (EOP) results for NSE; however, a characteristic trend in the distribution of results
for NSE and S100B was noted.
Although no clinical interpretation was applied to the
NSE and S100B results during the season, we include
the biomarker results in a summary table of outcome
measures for athletes sustaining a diagnosed SRC in
Table 3 and the individual results for each athlete in
Table 4. Only the post-injury SCAT2 had 100 % completion for all diagnosed SRCs among the concussion assessment tools while all venipunctures were completed
at the required time points. Of the 12 diagnosed concussions, 100 % (9/9) of the CNA and CSC assessments
conducted at the RTP time point had lower symptom
scores when compared to the post-concussive assessments consistent with approved protocols for RTP. For
S100B, 50 % (6/6) had RTP or EOS results lower than
Table 3 Combined outcome for concussion assessment tools
and biomarker results for diagnosed SRCs
Tool

Unit

POM

n

Min

Max

Mean

STDEV

Median

BESS

Error

Baseline

11

4

25

12.2

5.0

11

BESS

Error

Post

11

5

37

16.7

9.3

13

CNA

SC

Baseline

12

0

15

3.3

5.6

0

CNA

SC

Post

11

0

89

25.0

28.3

18

CNA

SC

RTP

3

0

1

0.3

0.6

0

SCAT2

SC

Post

12

2

102

39.1

28.6

34

CSC

SC

Post

9

0

91

22.1

31.4

7

CSC

SC

RTP

7

0

2

0.3

0.8

0

S100B

ng/L

Baseline

12

56

174

100.9

40.1

89

S100B

ng/L

Post

12

20

186

99

52.9

100

S100B

ng/L

RTP

12

28

170

78.6

45.8

66

S100B

ng/L

EOS

12

28

149

80.4

45.8

73

NSE

μg/L

Baseline

12

5.8

21.7

13.5

5.1

14

NSE

μg/L

Post

12

5.7

30.8

15.1

8.8

12

NSE

μg/L

RTP

12

4.9

14.6

10.3

4.3

9

NSE

μg/L

EOS

12

4.9

16.3

9.2

4.3

7

The presented data provide an overview over the total outcome of the
concussion assessment displayed by their unit (error during performance
(Error), Symptom score (SC), nanogram per liter (ng/L), microgram per liter
(μg/L), point of measurement (POM), sample size (n), minimum (Min),
maximum (Max), mean (Mean), and standard deviation (STDEV). The
assessment includes the score from the Balance Error Scoring System (BESS),
the score of the symptom charts of the Computerized Neuropsychological
Assessment (CNA), the Sport Concussion Assessment Tool 2 (SCAT2), and the
CSC (a symptom scale based on the University’s Concussion Program), as well
as the results of the blood-based biomarkers S100 Beta (S100B) and neuron-specific
enolase (NSE)

Schulte et al. The EPMA Journal (2016) 7:1
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Table 4 Individual outcome Symptom Charts
Tool

Unit

POM

1

2

3

4

5

6

7

8

9

10

11a

12a

25

4

14

*

13

11

10

11

11

10

11

14

Concussion symptom assessment
BESS

Error

Baseline

BESS

Error

Post

30

11

20

*

37

14

13

13

11

18

5

12

CNA

SC

Baseline

4

0

0

6

15

0

14

0

0

0

0

0

CNA

SC

Post

30

0

40

1

18

58

10

3

0

*

26

89

CNA

SC

RTP

*

*

0

*

0

*

*

*

*

*

*

1

SCAT

SC

Post

46

9

102

23

27

66

2

30

12

50

38

64

CSC

SC

Post

21

0

*

1

6

58

*

4

7

11

*

91

CSC

SC

RTP

0

*

*

0

0

0

*

*

*

0

2

0

S100B

ng/L

Baseline

69

72

75

85

136

138

174

111

111

56

140

44

S100B

ng/L

Post

172

51

29

126

115

186

143

65

106

93

82

20

S100B

ng/L

RTP

47

36

⊃

170

91

95

161

71

56

⊃

⊃

⊃

S100B

ng/L

EOS

42

38

43

53

94

149

175

99

99

61

84

28

NSE

ng/mL

Baseline

12.3

17.8

18.3

10.1

18.9

11.4

7.8

14.9

14.9

5.8

21.7

7.6

NSE

ng/mL

Post

30.8

11.5

7.9

11.5

10.2

24.6

14.1

16.4

30.5

6.3

11.3

5.7

Biomarker

NSE

ng/mL

RTP

14.6

7.8

⊃

9.6

7.5

14.1

11.5

13.7

19

⊃

⊃

⊃

NSE

ng/mL

EOS

6.4

6.2

6.9

6.6

7.5

9.7

15.2

16.3

16.3

8

5.9

4.9

The presented data show the individual outcome of the concussion assessment displayed by their unit (Error, Symptom score (SC), biomarker)), point of
measurement (POM), sample size (n), minimum (Min), maximum (Max), mean (Mean), and standard deviation (STDV). The assessment includes the score from the
Balance Error Scoring System (BESS), the score of the symptom charts of the Computerized Neuropsychological Assessment (CNA), the Sport Concussion
Assessment Tool 2 (SCAT2), and the CSC (a symptom scale based on the University’s Concussion Program), as well as the results of the blood-based biomarkers
S100 Beta (S100B) and neuron-specific enolase (NSE). Missing values are displayed with the symbol “*”. Some athletes were cleared to RTP at the EOS. Accordingly,
the symbol “⊃” indicates that the samples were drawn at the same time
a
Athletes with labeled IDs (IDa) were medically disqualified to RTP

the post-injury result with the other 50 % having higher
results at the RTP or EOS time points when compared
to the post-injury venipuncture. In contrast, 92 % of
NSE results (11/12) were lower at RTP or EOP time
points when compared to the corresponding post-injury
venipuncture. Of note, for athletes #11 and #12 who
were medically disqualified and unable to return to play,
the S100B concentration remained consistent with the
post-injury result while NSE decreased in concentration.
Interpretation of the data using the established reference
intervals resulted in 100 % of the baseline NSE and
S100B values for the 12 injured athletes below the upper
limit of the respective reference interval. For the postinjury samples, 100 % of the S100B results were within
the established reference interval while 25 % (3/12) of
the NSE results were above the upper limit of the reference interval. One hundred percent of the results for
S100B and NSE were within the established reference
intervals for the RTP and EOS samples.

Conclusions
In this study, we document the use of an interdisciplinary
workflow for venipuncture, on-site sample processing,
and central laboratory testing for the duration of an entire
collegiate football season. Not surprisingly, in following a

single, entirely male collegiate team, the overall sample size was limited in the number of concussions. In
addition, our results provide an evaluation of concussion
assessment tools in use at the time of manuscript preparation which did not include imaging studies as part of the
treatment protocol. Although the overall utility of the
biomarkers chosen for inclusion in our study remains
controversial, we have developed a successful strategy in
addressing the practical aspect of biomarker integration
into the routine concussion assessment workflow. Further,
by relying on clinically available assays, we provide an
interdisciplinary approach with biomarker results generated under the requirements of laboratory testing with
well-defined criteria for accuracy, reproducibility, and assay
performance not required in the research setting [12, 37].
Although the primary objective of the current study
was not to address the utility of S100B or NSE in diagnosing SRC, the results of the baseline venipuncture and the
reference intervals established from the dataset indicate
that for both S100B and NSE, the currently used reference
intervals are likely not applicable to athletes. This finding
is a common occurrence in laboratory medicine that often
prompts the necessary establishment of population
specific reference intervals. In the context of physical
activity, interpretation of established reference intervals
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can be further complicated [38, 39] and necessitates tight
control over experimental design and sample collection
for research as well as a well-defined protocol for eventual
implementation.
The introduction of biomarkers into athletics for SRC
diagnosis is a multi-faceted process and success of any
proposed biomarker or biomarker panels will rest largely
on the capability of successful implementation into the
current concussion assessment workflows. Although much
attention has been focused on biomarker discovery, the
presented study was designed to investigate the practicality
of biomarker implementation in a routine concussion
assessment workflow including venipunctures at key time
points before and after injury in addition to clinical assessments made for RTP for an entire collegiate football team.
Expert recommendations

As the discovery of novel biomarkers and biomarker
panels continues, successful implementation will rely on
a thorough understanding of the constraints of the entire system and how best to enact required protocols. A
continued need exists to identify and implement biomarkers with utility in all phases of the injury cycle with
careful attention given to the practical limitations inherent to the nature of athletic competition.

Additional file
Additional file 1: Table S1. Itemized venipuncture kits. (DOCX 14.2 kb)
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